Landscapes / Companies

Iovance Biotherapeutics, Inc. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
Approved
Next date
IOV-4001, Phase 1/2 trial completes
Drugs
4
in active trials · 9 in all
Trials
8 active
14 since 2021

Drugs4

DrugHow it worksPartnerStageNext dateDetails
Cell therapy
Approved Dec 2027Phase 2 trial completes
—
Phase 1/2 Sep 2027Phase 1/2 trial completes
—
Phase 1/2 Jun 2032Phase 1/2 trial completes
—
Phase 1/2 Mar 2034Phase 1/2 trial completes

About

No active trial
IL-2, IOV-2001, LN-145-S1, LN-145/LN-144, Nivolumab-relatlimab
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Iovance Biotherapeutics, Inc.

Following is part of Solo: you see every change to Iovance Biotherapeutics, Inc. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in